euNetworks Forms Exclusive Partnership on CrossChannel Fibre System to Deliver Ultra-Low Latency Services Between London and Madrid
28.3.2023 09:00:00 CEST | Business Wire | Press Release
euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced that it has entered into an exclusive partnership agreement with Crosslake Fibre UK Limited (“Crosslake”), an international network provider and developer of unique subsea and terrestrial fibre networks. This partnership relates to Crosslake’s new CrossChannel Fibre system and gives euNetworks exclusivity to deliver ultra-low latency services between the United Kingdom and Madrid on this system to the financial services community. euNetworks has also agreed to a strategic relationship, enabling the sale of dark fibre services by euNetworks using the system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230328005180/en/
Paula Cogan, CEO of euNetworks (Photo: Business Wire)
CrossChannel Fibre is a 550km cable system with end-to-end fibre running between Slough, United Kingdom and Paris, France and is the first subsea cable to be built across the English Channel to France in over 20 years. This high fibre count, non-repeatered system contains 96 fibre pairs, each enabling over 20 terabits per second of capacity throughput. It is the lowest latency fibre network between London and Paris. The route is designed with optimal spacing and attenuation/ loss between amplifier sites, requiring just four sites, compared to typically between seven and nine on other routes. This reduced number of ILA’s, combined with free air passive cooling at each ILA site enables a much lower power consumption per bit and it delivers an optimised low-carbon footprint network infrastructure.
euNetworks focuses on delivering high bandwidth data centre-to-data centre connectivity between and within European cities, owning, operating and building duct and fibre-based critical Internet infrastructure. The company has provided market-leading fibre-based optical ultra-low latency services to the high-frequency trading community for several years through its dedicated network platform, euTrade. This new London to Paris system offers customers ultra-low latency to Madrid and additional options and onward connectivity to the rest of Europe.
“We’re delighted to be working with Crosslake and being able to exclusively offer our euTrade ultra-low latency solution on CrossChannel Fibre to the financial sector,” said Paula Cogan, Chief Executive Officer of euNetworks. “CrossChannel is a new system serving an important connectivity route between the UK and the continent.”
“CrossChannel Fibre is the latest next-generation system to support the ever-growing connectivity needs between London and Paris,” said Mike Cunningham, Chief Executive Officer of Crosslake. “The cables on current routes have limited amounts of available capacity and are aging after over two decades of operation. Our system delivers a new unique route, approaching Paris from the North West, and is therefore diverse from existing systems. That’s an important differentiator to the segments CrossChannel serves – wholesale carriers, data centre operators, content, cloud and network service providers, hyperscalers, government agencies, media and entertainment, and financial services. euNetworks is highly focused on delivering high bandwidth services to these segments. Their strong position and service performance in the demanding ultra-low latency market sets them apart, and we’re excited to be working with them.”
“euNetworks builds and invests in long haul fibre networks to connect the key data centre hubs across Europe,” said Cogan. “Those networks support our customer’s future connectivity needs and are critically important to business today. “We delivered our first Super Highway in 2019, linking Dublin via our submarine cable Rockabill to Manchester, London and Lowestoft. In 2021 we delivered our second Super Highway, including Scylla, the first subsea cable linking the UK and the Netherlands in two decades. We build Super Highways on the long-haul routes that we believe are critical to Europe’s future international connectivity needs. We use low-loss fibre on these routes to deliver a low cost per bit long haul solution. Crosslake’s new system running from London to Paris aligns with our long haul network development strategy, delivering a uniquely routed next-generation high capacity infrastructure.”
About euNetworks
euNetworks is a critical bandwidth infrastructure company, owning and operating 17 fibre based metropolitan networks connected with a high capacity intercity backbone covering 53 cities in 17 countries across Europe. The company leads the market in data centre connectivity, directly connecting over 500 today. euNetworks is also a leading cloud connectivity provider and offers a targeted portfolio of metropolitan and long haul services including Dark Fibre, Wavelengths, and Ethernet. Wholesale, finance, content, media, mobile, data centre and enterprise customers benefit from euNetworks’ unique inventory of fibre and duct based assets that are tailored to fulfil their high bandwidth needs. For further information visit eunetworks.com.
About Crosslake Fibre
Crosslake Fibre is a developer, owner and operator of telecommunications networks in North America and Western Europe. Its innovative approach to fibre-optic development is focused on providing wholesale, enterprise, and financial customers with physically diverse, low-latency connectivity over next-generation networks.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230328005180/en/
Contact information
euNetworks contact:
Hannah Britt | Chief Marketing Officer | euNetworks
5 Churchill Place | London E14 5HU
hannah.britt@eunetworks.com email | +44 7717 896 446 mobile
Crosslake contact:
Fergus Innes | CCO | Crosslake Fibre
fergus@crosslakefibre.ca email
+1 416 613-6200 phone
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
